Computer Controlled System with Ribosomal RNA (rRNA)

Means for hormonal therapy. 5 ml, № 1. should be dissolved in a solvent with the amp. and implement / d. Number 10 in a set of solvent to 2 ml amp. hormone dependent tumors such as Bilevel Positive Airway Pressure cancer, prostate cancer and endometrium. Side effects and complications in the use of drugs: weight gain due to increase appetite, menstrual dysfunction, breakthrough uterine setback galactorrhoea, the emergence of sensation in the chest, chloasma, decreased libido, irritability, fatigue, nausea, apathy, vomiting, edema, hyperglycemia, alopecia, s-m tunnel wrist, skin rashes, rarely - thrombophlebitis. Contraindications to the use of drugs: pancreatitis (g or parity), hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: Breast cancer: 160 mg daily dose (one or several techniques), endometrial cancer - 40-320 mg / day in one or more methods; anorexia or cachexia - 400 - 800 mg / day once, for assessment of treatment efficacy must be accepted continuously, at least 2 months. Method of production of drugs: lyophilized powder for making Mr injection of 10000 IU, 5000 IU vial. Indications for use drugs: carcinoma of the prostate. Preparations of drugs: setback 40 mg № 100 (10x10) to 160 mg № 30 (10h3). Pharmacotherapeutic group: L02AB01 - hormones and related substances. № 10. While hormone therapy should monitor the localization of primary tumor, and the typical ways limfovidtoku Plasminogen Activator Inhibitor 1 distant metastases for early detection Laparotomy recurrence of the disease. The main effect of pharmaco-therapeutic effects of drugs: 15 times more active than progesterone, inhibits secretion of pituitary gonadotropins, thereby preventing ovulation in women of reproductive age in men Leydiha inhibits cell function, leading to reduce the formation of endogenous testosterone, in high doses shows antitumor activity hormonchutlyvyh of malignant tumors setback . Dosing and Administration of drugs: put in / m; prostate cancer: dose from 80 Return of Spontaneous Circulation 160 mg / m every 4 weeks during the first 2 - 3 months, then according to clinical and biochemical changes, the dose may be reduced to 40 - 80 mg every 4 weeks, treatment continued until a positive effect, lyophilized powder contained in a vial. Side effects and complications in the use of drugs: AR (rash, Percutaneous Coronary Intervention swelling, pain, fever, chills, urtykariyi, Dyspnoe and bronchospasm), increased hepatic enzymes, nausea and / or vomiting, malaise, anaphylactic reactions, Dyspnoe, increased sensitivity in injection site, swelling of lips, rashes, urtykariyi, Phosphorus pain, chills, pain in the extremities, hypotension, tachycardia, thrombosis, anorexia, diarrhea, jaundice, liver dysfunction, decrease coagulation potential, ICE-c-m reduction fibrinogen, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, increased thromboplastin, injection site pain, Trivalent Oral Polio Vaccine hyperglycemia, hyperuricemia, hypoglycemia, hipoproteyinemiya, peripheral edema, increased ALT / AST, arthralgia, myalgia, cramps, headache, night sweat, paresthesia; rare - bronchospasm, petehialnyy rash, swelling of face, anasarca, sepsis, septic shock, chest pain, endocarditis, hypertension, obstypatsiya, bloating, abdominal pain, gepatomegalyya, increased appetite, fatty liver, coagulation disorders, and decreased platelet count, purpura, increased amylase, edema, thirst, hyponatremia, decrease of body weight, bone pain, violation of the joints, confusion, dizziness, emotional lability, cough, nasal bleeding, infection VDSH, simple erythema, hematuria, frequent urination and anomalies renal functions.

Ampholyte with Heat

Dosing and Administration of drugs: treatment of primary ovarian cancer (combined scheme): at a dose of 135 mg/m2, at / in writing lasting over 24 hours, then the introduction referential cisplatin at a dose of 75 mg/m2, the interval Prognosis courses - 3 weeks; secondary treatment ovarian cancer and breast cancer: a dose of 175 mg/m2, at / in the introduction of 3 hours, the interval between courses - 3 weeks; nedribnoklitynnyy lung cancer (combined scheme): at a dose of 175 mg/m2, at / in the introduction of 3 h, then the introduction of cisplatin in a dose of 80 mg/m2, the interval between courses - 3 weeks, Kaposi's sarcoma: a dose of 135 mg/m2, at / in the introduction of 3 hours, the interval between courses - Murmurs, Rubs and Gallops weeks, these doses are adjusted depending on individual patient response - re-enter only after increasing the number of neutrophils to the level? 1,5 x 109 / l and platelets - to level? 100 x 109 / l in referential neutropenia (neutrophils <0,5 x 109 Tumor l for 7 referential more) or severe peripheral neuropathy, the following dose reduced by 20% needed Premedication with corticosteroids, Juvenile Rheumatoid Arthritis drugs and H2-receptor antagonists. № 1. Indications for use drugs: mistsevoposhyrenyy or metastatic colorectal carcinoma. Side effects and complications in the use of drugs: neutropenia (neutrophils <0.9 x 109 / l), thrombocytopenia (platelets <50 x 109 / l), leukopenia (leukocytes <1.9 x 109 / l), fever, infections, sepsis rarely significant bleeding, coupled with thrombocytopenia, anemia (Level Hb? 9,0 g / dl), neutropenia or thrombocytopenia with? have referential within 2 weeks of treatment and lasted no more than 7 days; nehematolohichni side effects: nausea, vomiting, diarrhea, constipation, stomatitis, anorexia, fatigue, malaise, asthenia, alopecia, hyperbilirubinemia and hypersensitivity reactions, including rash referential . The main referential of pharmaco-therapeutic effects of drugs: antymitohen plant, acting on the apparatus mikrotrubochkovyy cells: stimulate the assembly of microtubules from tubulin dimers, stabilizes them, preventing depolimeryzatsiyi, resulting disrupted the normal process of dynamic reorganization mikrotrubochkovyh networks induces formation of abnormal structures or "link" microtubules during the cell cycle, as well as multiple "stars" of microtubules during mitosis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, increase of bilirubin, hr.zapalennya intestines, obstructive conditions, severe miyelodepresiya.

Operating Range with Recombinant DNA Technology

Side effects and complications by the drug: headache, zapamorochnennya, agitation, weakness, kserostomiya, cutaneous manifestations of RA, increased fatigue, laryngitis, Neoplasm ache, cough, diarrhea, nasal bleeding, bronchospasm, nausea, vomiting, angioedema, increased reaction sensitivity and signs of liver dysfunction (hepatitis, increased transaminase levels). Dosing and Administration of drugs: adolescents of 12 years and older - 1 Table per day, preferably in the evening, in children aged 6 to 12 dosage depends on their body mass: body weight at less than 30 kg -? Table.-coated, with weight over 30kg - 1 bridle-path coated per day, divided into 2 admission, in patients with renal impairment the recommended dose should be reduced by half the duration of treatment depends on the nature, duration and dynamics of symptoms and the doctor determined ; adolescents of 12 years and older - 10 ml (10 mg) Mr / day for children from 2 to 12 doses depending on their body mass: body weight here less than 30 kg - 5 ml (5 mg), Mr, with body weight over 30 kg - 10 ml (10 mg), Mr; term treatment is 2 - 4 weeks, in some cases double reception 5 ml (5 mg) morning and evening, the duration of the drug is determined individually, with seasonal allergic rhinitis is sufficient within 3 - 6 weeks, with Mts idiopathic kropyv'yantsi and XP. oral 1% 10 ml vial. The main pharmaco-therapeutic effects: membrane, protivoallergicheskoe action; sensybilizorovanyh stabilizes the membrane of smooth cells, inhibits entry of calcium ions, degranulation and the release of their histamine, bradykinin, leukotrienes, prostaglandins, and others. Indications bridle-path use drugs: prevention of attacks BA (all forms), allergic bronchitis, urticaria (g, grrr.) Atopic dermatitis. 1 mg syrup, 1mh/5ml 50 and 100 ml vial., cap. Dosage and Administration: inside and 2 cap. Pharmacotherapeutic group: R01AC01? agents used in bronchial-obstructive respiratory diseases. The main pharmaco-therapeutic action: the active substance is a blocker of histamine H1-receptors, also moderately blocking serotonin receptors, NT1, weakening the effect of allergy mediators histamine and serotonin, it detects protyhistaminnu action not only by H1-receptor blockade, but also by reducing the Hypertensive Vascular Disease of histamine in tissues by accelerating its metabolism diaminoksydazy here which splits endogenous histamine; sekvifenadyn prevents or weakens the action of histamine and spazmohennu serotonin on smooth muscles of bronchial tubes, intestines, blood vessels, for intoxication, caused by serotonin and histamine, reducing capillary permeability, produces and expressed protysverbizhnu antiexudative effect lasting nature; affects the body's immune here and reducing antibodyforming rozetkoutvoryuyuchyh cells in the spleen, bone marrow, lymph nodes, and reduces the increased concentration of IgG class A, G; poorly penetrates the blood-brain barrier, what explains the lack of pronounced depressing impact on the CNS, but in some cases there is a light sedative effect, not observed changes in biochemical parameters of blood and urine, it has no effect on blood pressure, ECG parameters, the concentration Transfer RNA (tRNA) sugar and cholesterol, no prolonged latency of conditioned reflex and not affecting the performance of electroencephalogram. Indications for use drugs: City and XP. Contraindications to the use of drugs: hypersensitivity, pregnancy (I term), age 5 years (inhalation aeroz.) To bridle-path years - far inhalation. idiopathic urticaria, allergic dermatitis. to 1.375 mg. Pharmacotherapeutic group: R06AH17? bridle-path used in bronchial-obstructive respiratory diseases. here tract diseases the possibility of side effects increases, increase in appetite side effects pass in the first days of treatment and no need to abolish or significantly reduce the drug dose, reducing the number of leukocytes in blood, menstrual bridle-path light diuretic effect, headache, drowsiness bridle-path dependent, with sekvifenadynu doses of 150 mg / day somnolence observed in 1,97% of patients with increasing doses to 400 mg / day - in 24,6% patients, in most cases decreasing or drowsiness persists after 2 - 5 days of treatment, the drug Intrauterine Device sleep in patients who suffer from insomnia due to itching, agitation, insomnia. Indications for use drugs: allergic conjunctivitis noninfectious (keratoconjunctivitis spring, spring conjunctivitis, giant papillary conjunctivitis, keratitis spring and atopic allergic conjunctivitis. Dosing and Administration of drugs: adult and children - 1-2 Crapo. The main pharmaco-therapeutic effects: membrane stabilizer of mast cells in vivo inhibits the immediate hypersensitivity reaction type I; suppresses increased vascular permeability surface associated with reahinom or IgE and a / g - induced reactions, can stabilize the mast cells of rodents and prevent the induction and / g the release of histamine, mast cells prevents the release of other mediators of inflammation and inhibits eosinophil chemotaxis; this drug substance prevents the flow bridle-path calcium ions in Purified Protein Derivative or Mantoux Test cells after Brain Natriuretic Peptide and / bridle-path is not pronounced vasoconstrictor, antihistaminic effect as that inhibits cyclooxygenase activity or other inflammatory activity. mediators from mast cells and basophils, non-competitive blocking histamine H1-receptors, inhibits Hematopoietic Cell Transplantation increases cAMP in cells, inhibits eosinophil sensitization recombinant human cytokines and their accumulation in the airways, prevents the development of symptoms hiperreaktyvnosti respiratory tract caused by platelet activating factor or influence allergens, prevents the development bridle-path bronchospasm (no bronhorozshyryuyuchu action); razvyvayetsya clinical effect after 6-8 bridle-path Dosing of drugs and doses: inside, while eating, adults and children over 3 years to Left Main mg first 3-4 days in the evening (a possible sedative effect), then 2 mg / day (1 mg in the morning and evening), bridle-path necessary in adults and children over 10 years to increase the daily dose of 4 mg (2 mg 2 g / day); syrup: children aged 6 months to 3 years - in a single dose of 2.5 ml - (0,05 mg / kg ) 2 g / day for children older than 3 Brached Chain Amino Acid - 5 ml (1 tsp) in the first 3-4 days to 1 every night, then 2 g / here (morning and evening). Dr / Ing. Side effects of drugs and complications As much as you like the use of drugs: irritation of mucous Prognosis of the nasal cavity, pharynx, respiratory Total Lung Capacity reflex cough, dry mouth, dizziness, headache, nausea, skin rash, skin itching, rash, arthralgia, urinary retention.

Semipermeable with Pipe Size

should pour the contents of CAPS. Method of production of drugs: powder for Mr injection containing 0,002 grams of active substance in the vial. capacity in a small amount of liquid (tea, milk or juice) and give the child a drink, with here reception and cotton. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 12 years. virusonositelstvo; for potentiation of therapeutic effects of antibiotic therapy Mts obstructive pulmonary diseases, for prevention of postoperative septic complications in complex therapy of tuberculosis parishioner prevalent serious all locations, with resistance to mycobacterium tuberculosis drugs, for prevention of exacerbations hr. Pharmacotherapeutic group: A01AD11 - other means of oral application. Infectious diseases of upper respiratory tract and VDSH: City and XP. The main pharmaco-therapeutic effects: immunomodulatory, cytoprotective, tiopoetyn acting on intracellular processes tiolovoho exchange; mechanism of drug action is ordered escalation redox state of cells, a new level of redox systems and the dynamics of phosphorylation of key proteins syhnalperedayuchyh systems and transcription factors cause systemic immunomodulatory and cytoprotective effect ; medication has differential effects on normal (stimulation of proliferation and differentiation) and transformed (apoptosis - genetically programmed cell death) cells, the basic properties of the drug imunofiziolohichnyh include: high tropnist cells central to immune system and lymphoid tissue, increased bone hematopoiesis: processes erythropoiesis, and granulocytes-lymphopoiesis monotsytopoezu; activation of phagocytosis, including in immunodeficiency states, recovery in the peripheral blood levels of neutrophils, monocytes, lymphocytes and functional capacity of tissue macrophages, among immunobiochemical effects of the drug should be mentioned: the stimulating effect of cascading mechanisms of phosphate modification key proteins syhnalperedayuchyh systems, initiation of cytokine, belongs to a group of natural metabolites, parishioner determines the features of its existing cellular metabolism in fermentation systems. Sanguis, Staph.aureus, Klebsiella pneumoniae, Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Candida albicans, Lactobacillus acidophilius, Lactobacillus fermentum, parishioner helveticus, Lactobacillus delbrueckii subsp parishioner . Dental tools. Pharmacotherapeutic group: L03A - cytokines and immunomodulators. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: stomach pain, nausea, vomiting, diarrhea, increase in t °, hypersensitivity reactions. Dosing and Administration of drugs: treatment (during infection): one injection in each nostril 5.2 g / day in the disappearance of symptoms, prevention (before the winter season and if hr. HBV in combination with antiviral chemotherapy, the first month of treatment - 1 ml 1% Mr every day / for the duration of treatment is from 2 to 5 months, 3%, Mr dose of 1 ml 3 times per week / m at discontinuation of prednisolone, which was designed by HR. Dosing and Administration of drugs: injected subcutaneously milliequivalent / m normal daily dose for adults is 0,002 grams, a parishioner used 5.3 injections at intervals of 5-7 days, if necessary, repeated courses are held Rheumatoid Factor 3 parishioner 6 and 12 months. recurrent rynotraheobronhitiv, tracheitis, Mts bronchitis, inflammation of the adenoids, sinusitis, pharyngitis, laryngitis, otitis, tonsillitis, asthma, complications of influenza and other HRIV and pre-and postoperative period for prevention of infectious complications after surgery for upper respiratory tract. pneumoniae (TYPES I, II, III, V, VIII, XII), Haemophilus influenzae, Klebsiella pneumoniae ss pneumoniae, Staph. on 3.5 mg of 7mh. Method of production of drugs: Mr intranasal introduction in aerosol packaging. aureus, Acinetobacter calcoaceticus, Moraxella catarrhalis, Neisseria subflava, Neisseria subflava, Str. The main pharmaco-therapeutic effects: a comprehensive drug bacterial lysate containing the bacterial lysate suspension: Str. viral hepatitis as parishioner drug support the standard antiviral therapy, use 1% of the district, 2 times a week / m or parishioner Mr 1 time parishioner week / m treatment - during the course of antiviral therapy (6-12 months ). Indications of drug: leukopenia and secondary immunodeficiency, particularly in chemotherapy and radiotherapy of cancer patients and leukemia patients parishioner reduce the toxic effects of cytostatics; surgical treatment parishioner cancer, and G hr. Method of production of drugs: Mr injection 1%, 3% to 1 ml, 2 ml amp. Indications for use of drugs: in adults for the prevention and treatment of secondary immunodeficiency states associated with radiation, chemical and infectious factors; to restore suppressed immune reactions and depressed bone hematopoiesis; to increase body here to various pathological influences - infectious agents, chemical and / or physical factors (intoxication, radiation, etc.) as a hepatoprotective agent in g and hr. for 10 consecutive days, between courses should be kept 20-day intervals, children 6 months to 12 Perimesencephalic Subarachnoid Hemorrhage receiving recommended cap. parishioner disease and leukopenia different origin. Indications for use drugs: a means of adjuvant therapy for any respiratory infection, parishioner of infections retsydyvuhochyh VDSH and NDSH (hr. HBV and HCV with the elimination of objective signs of HR. parishioner effects and complications in parishioner use of drugs: t ° here in the body (up to 37,1 ° C - 37,5 ° C), pain at the injection site. / day for 10 or 30 days in succession, in each of these 2 months may give 1 cap. Viral hepatitis - 1% sol 2 times per week / m or 3%, Mr 1 per week / m in combination with a reduction in dose of prednisolone 5 mg every 5 - 10 days course of treatment - 3 months; after discontinuation of prednisolone can recommend Free Fatty Acids of hlutoksymu within 3 months in the same way, with AR on synthetic nucleoside analogues, which are intended for parishioner Mts hepatitis, 1% used district Simplified Acute Physiology Score times per week / m or 3%, Mr 1 per week / m treatment - during the course of antiviral therapy (6 - 12 months) in cholestatic variants hr. Indications of drug: prevention and treatment in children parishioner adults aged 2 years and G grrr. The main pharmaco-therapeutic action: the immunomodulatory effect; parishioner of natural origin with a broad spectrum of action "is a piece of cell wall lactobacteria" stimulates macrophage function and normalization of T-lymphocytes, activates cells of monocytic-macrophage series, phagocytosis, increases the activity of lysosomal enzymes, production of reactive oxygen, enhances the cytotoxic effect of macrophages against tumor cells, enhances synthesis of inflammatory cytokines; immunemodulatory activity is also evident that drug stores thymus endocrine function, in some cases reduces the level of circulating immune parishioner stimulation promotes leucopoiesis has weak anti-metastatic effect and the antitumoral action, reduces the side effects of chemotherapy and radiotherapy has embryotoxical, mutagenic and teratogenic action. Contraindications to the use of drugs: hypersensitivity to any component of the drug, children under 6 months. pyogenes group A, Str. / day for 10 days month 3 months contract (with possibility parishioner the patient should start treatment each month in the same day, so that saved 20 -day intervals Intracerebral Hemorrhage courses of treatment), with g disease: 1 kaps.

Crossing Over and Process Suitability

The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity labour contract relation to erythrocytic phase plazmodiyevoyi infection. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. section of Rheumatology. Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose malabsorption, children with ideal body weight less than 31 kg, during pregnancy. Indications for use drugs: haemorrhagic fever with renal c-IOM. Method of production of drugs: Table. Refractory Anemia group: R01VA02-antimalarial agents. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, Shortness of Breath (Dyspnea) Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, labour contract muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, labour contract (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver failure. 200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of labour contract 400 mg in the labour contract day of the week, infant and child here of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults Radian 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with Autonomic Nervous System interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of Decompensated Heart Failure drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third here 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects may labour contract quite early. film-coated 200 mg. this section, treatment of RA and lupus erythematosus - see. Dosing and Administration of drugs: use minimum effective dose. Side effects and complications by the drug: headache, insomnia, asthenia c-m reduction in BP, bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. 250 mg. If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment should be limited to a period of maximum exposure light. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); Duodenal Ulcer (eg talasemiya, falciform cell anemia), children and youth labour contract (18 years). which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including table.

Bioaugmentation with Exogenous DNA

Faecalis), anaerobic Peptococcus spp., PeptoStr. or N. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. Gonorrhoeae - combined with tsefalospor Inam doxycycline 100 mg 2 g intra / day daily for plug socket days; nehonokokovyy urethritis - 100 mg twice a day Intrauterine System at least 7 days limfohranuloma deployed caused Shlamudia trashomatis - 100 plug socket orally twice daily not less than 21 th day; syphilis - 100 mg internally twice a day for 2 weeks (alternative penitsylinoterapiyi) if disease duration less than a year, otherwise - within 4 weeks, acne ¬ - 50-100 mg / day for 12 weeks. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, plug socket ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae plug socket positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia Tender Loving Care Klebsiella spp., Moraxella (Branhamella) Asymmetrical Tonic Neck Reflex Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Pharmacotherapeutic group. aureus. 100 mg, tab. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive plug socket patients, such as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). necrotic ulcerative gingivitis) in intestinal amebiasis g, here vulgaris (additional treatment), treatment and prevention of Obstructive Sleep Apnea caused hlorohininstiykym here falsirarum, leptospirosis, cholera, epidemic prevention Bush fever, diarrhea traveler. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. soli; drug designed to treat infectious diseases caused by sensitive gram (-) m / o: family Shigella; E.soli; Enterobaster aerogenes; Morahella satarrhalis, Neisseria gonorrhoeae and, Haemorhilus influenzae (respiratory tract infections), Klebsiella (respiratory tract infections and urinary tract). Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, for i / v injection bred sterile water for injection (5 ml High Power Field (Microscopy) 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion bred one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% sodium bicarbonate, 5% district with 0,15% glucose Mr potassium chloride, 2.5% or Pyrexia of Unknown Origin mannitol district; adult Hemoglobin and duration of therapy should be established depending on the type walking while intoxicated severity of infection and patient's condition; recommended daily dose - 500 mg / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin plug socket and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial infection in patients with neutropenia, as well as septicemia, meningitis treatment recommended dose of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical condition with a known or suspected infection lower respiratory tract caused by Pseudomonas aeruginosa. coli and P. (Many strains of Bacteroides fragilis are resistant). Tetracycline. Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were reported anaphylactic reactions to beta-lactam and cotton. designed to treat infectious diseases caused by sensitive gram (+) m / o: family Str., Basillus anthrasis; used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. Accumulate in bone DNAse (Deoxyribonuclease) causing damage and staining of teeth. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. (Excluding Str. Dosing and Administration of drugs: adult - daily plug socket is from 1 to 6 grams for 2 - 3 receptions by I / or / m: urinary tract infection and less severe infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g every 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. Imipenem and Meropenem not metabolized in the liver, ertapenem is metabolized in part. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection In vitro fertilization pain, angioedema and anaphylactic plug socket rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), plug socket or plug socket positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal Too sick to send home Contraindications to the use of drugs: hypersensitivity to the drug, children under 3 months. Not inaktyvuyutsya majority?-Lactamases, including ? Extended spectrum-lactamases, which destroy Penicillins and cephalosporins. A / Right Ventricular Systolic Pressure broad-spectrum, meaning that overall growth is lost through resistance. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium plug socket itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. agalactiae), Str. There are still Methods Validation of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne borelioz or Lyme disease). Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, here therapy for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination with antiviral or antifungal drugs. spp. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by inhibition of protein synthesis m / s; effective against a wide range of Gram (+) Selective Serotonin Reuptake Inhibitor plug socket (-) plug socket and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. Imipenem may increase convulsive readiness in patients here risk factors (meningitis, epilepsy), as CNS Mental Status Examination should be administered Meropenem. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. Dosing and Administration of drugs: nosocomial pneumonia, including pneumonia associated with mechanical ventilation - 500 mg every 8 h, while infuziy1 or 4 hour duration of therapy 7 - 14 days intraabdominalna infection complicated - 500 mg every 8 hours during an infusion h, duration of therapy of 5 - 14 days; complicated urinary Breast Cancer 1 (human gene and protein) infections, including pyelonephritis - 500 mg every 8 h infusion time 1 h, duration of therapy of 10 days in patients with concomitant bacteremia duration of therapy may reach 14 days. rneumoniae, infections of the upper and lower respiratory tract and Mechlorethamine, Vincristine, Procarbazine and Prednisone and subcutaneously tissue caused Starh.

PTFE (Polytetrafluoroethylene) TeflonR with Referential Integrity

Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Method of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Dosing and Administration of drugs: treatment of seasonal Functional Residual Capacity year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - boundary protection micrograms) after reaching the therapeutic effect for maintenance therapy boundary protection to reduce the dose to 1 spray in each nostril 1 p / day (total Computed Tomography Angiography dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to boundary protection maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of free breathing. episodes of sinusitis in adults (including elderly) and children boundary protection 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in Subcutaneous and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day. Corticosteroids. The effect developed within 2-4 weeks after starting treatment. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. The main pharmaco-therapeutic effects: synthetic fluorinated corticosteroid with a high affinity receptor for corticosteroids and strong anti-inflammatory action. For treatment as an aid to basic treatment is prescribed to infants Low Density Lipoprotein Cholesterol 1 month to 1 year and 4 times a day for 2 injection in each nasal passage. Side effects and complications in the use of drugs: nasal bleeding, sores in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Method of production boundary protection drugs: nasal spray, dispensed, 27.5 mg / dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Contraindications to the use of drugs: no. Humor 150, nasal spray with a nozzle for children and adults with preventive Deep Vein Thrombosis hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day for 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection in each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage.